Monomethyl auristatin E

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Monomethyl auristatin E
Monomethylauristatin E.svg
Identifiers
Abbreviations MMAE
CAS number 474645-27-7 N
PubChem 11542188
ChemSpider 9716967 N
Jmol-3D images Image 1
Properties
Molecular formula C39H67N5O7
Molar mass 717.98 g mol−1
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
 N (verify) (what is: YesY/N?)
Infobox references

Monomethyl auristatin E (MMAE) is a synthetic antineoplastic agent. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked to a monoclonal antibody (MAB) which directs it to the cancer cells. In International Nonproprietary Names for MMAE-MAB-conjugates, the name vedotin refers to MMAE plus its linking structure to the antibody.[1] It is a potent antimitotic drug derived from peptides occurring in marine shell-less mollusc Dolabella auricularia called dolastatins which show potent activity in preclinical studies, both in vitro and in vivo, against a range of lymphomas, leukemia and solid tumors. These drugs show potency of up to 200 times that of vinblastine, another antimitotic drug used for Hodgkin lymphoma as well as other types of cancer.[2]

MMAE is actually desmethyl-auristatin E; that is, the N-terminal amino group has only one methyl substituent instead of two as in auristatin E itself.[2]

Mechanism of action[edit]

Monomethyl auristatin E is an antimitotic agent which inhibits cell division by blocking the polymerisation of tubulin. The linker to the monoclonal antibody is stable in extracellular fluid, but is cleaved by cathepsin once the conjugate has entered a tumour cell, thus activating the antimitotic mechanism.[3][4]

Structure of a MMAE-MAB-conjugate. The linker, consisting of the amino acids valine (Val) and citrulline (Cit), is cleaved by cathepsin inside tumour cells.[5]
The spacer (paraaminobenzoic acid) is marked green, the cathepsin-cleavable linker is blue, and the attachment group (consisting of maleimide and caproic acid) is brown. The whole radical inside the four boxes is called vedotin.

Monoclonal antibodies[edit]

MMAE has been tested with various monoclonal antibodies.

See also[edit]

References[edit]

  1. ^ Statement on a nonproprietary name adopted by the USAN Council: Vedotin
  2. ^ a b Dosio, F.; Brusa, P.; Cattel, L. (2011). "Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components". Toxins 3 (12): 848. doi:10.3390/toxins3070848.  edit
  3. ^ a b Seattle Genetics: Brentuximab vedotin (SGN-35)
  4. ^ a b Francisco, Joseph A; et al. (2003). "cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity". Blood 102 (4): 1458–1465. doi:10.1182/blood-2003-01-0039. PMID 12714494. 
  5. ^ A. Klement (13 May 2013). "Sprunginnovation beim Hodgkin-Lymphom: Adcetris". Österreichische Apothekerzeitung (in German) (10/2013): 67f. 
  6. ^ Medical News Today: CuraGen Announces Expansion Of CR011-vcMMAE Phase II Trial In Advanced Breast Cancer
  7. ^ NCI Drug Dictionary: Glembatumumab vedotin